Company intelligence / Profile preview

Flame Biosciences

New York, New York, United Statesinvestors.leaptx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Flame Biosciences was a clinical-stage biopharmaceutical company focused on developing transformative therapies for cancer and inflammatory diseases. Its pipeline included monoclonal antibodies targeting Claudin18.2 and IL‑1β for solid tumors and inflammation-related indications. The company’s lead asset FL‑301 targeted Claudin18.2 in pancreatic cancer and reached Phase 1 trials in China before the program was discontinued following acquisition by Leap Therapeutics in January 2023. All active development under the Flame name has ceased.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodySmall molecule
Industry: Biotech

Drug pipeline

1 asset

FL-301

Phase 1

Indications: Cancer

Partnerships

NovaRock Biotherapeutics (for acquisition of CLDN18.2 asset)

Beyond the preview

Go deeper on Flame Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flame Biosciences.

Explore the full profile